|
1
|
Msemburi W, Karlinsky A, Knutson V,
Aleshin-Guendel S, Chatterji S and Wakefield J: The WHO estimates
of excess mortality associated with the COVID-19 pandemic. Nature.
613:130–137. 2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z,
Xiang J, Wang Y, Song B, Gu X, et al: Clinical course and risk
factors for mortality of adult inpatients with COVID-19 in Wuhan,
China: A retrospective cohort study. Lancet. 395:1054–1062.
2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Asrani SK, Devarbhavi H, Eaton J and
Kamath PS: Burden of liver diseases in the world. J Hepatol.
70:151–171. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Marjot T, Moon AM, Cook JA, Abd-Elsalam S,
Aloman C, Armstrong MJ, Pose E, Brenner EJ, Cargill T, Catana MA,
et al: Outcomes following SARS-CoV-2 infection in patients with
chronic liver disease: An international registry study. J Hepatol.
74:567–577. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng
Q, Meredith HR, Azman AS, Reich NG and Lessler J: The incubation
period of coronavirus disease 2019 (COVID-19) from publicly
reported confirmed cases: Estimation and application. Ann Intern
Med. 172:577–582. 2020.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang
H, Wang T, Zhang X, Chen H, Yu H, et al: Clinical and immunological
features of severe and moderate coronavirus disease 2019. J Clin
Invest. 130:2620–2629. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Abdo-Francis JM, Moreno-Alcantar R,
Pérez-Hernández JL, Remes-Troche JM, Velasco AV, Cerda-Reyes E,
Tijera FH and Castro-Narro G: Impact of COVID-19 on pre-existing
liver disease. Cir Cir. 92:131–136. 2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Iavarone M, D'Ambrosio R, Soria A, Triolo
M, Pugliese N, Del Poggio P, Perricone G, Massironi S, Spinetti A,
Buscarini E, et al: High rates of 30-day mortality in patients with
cirrhosis and COVID-19. J Hepatol. 73:1063–1071. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhang C, Shi L and Wang FS: Liver injury
in COVID-19: Management and challenges. Lancet Gastroenterol
Hepatol. 5:428–430. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhou YJ, Zheng KI, Wang XB, Sun QF, Pan
KH, Wang TY, Ma HL, Chen YP, George J and Zheng MH:
Metabolic-associated fatty liver disease is associated with
severity of COVID-19. Liver Int. 40:2160–2163. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Khadke S, Ahmed N, Ahmed N, Ratts R, Raju
S, Gallogly M, de Lima M and Sohail MR: Harnessing the immune
system to overcome cytokine storm and reduce viral load in
COVID-19: A review of the phases of illness and therapeutic agents.
Virol J. 17(154)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Coperchini F, Chiovato L, Croce L, Magri F
and Rotondi M: The cytokine storm in COVID-19: An overview of the
involvement of the chemokine/chemokine-receptor system. Cytokine
Growth Factor Rev. 53:25–32. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hirano T and Murakami M: COVID-19: A new
virus, but a familiar receptor and cytokine release syndrome.
Immunity. 52:731–733. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Henry BM, de Oliveira MHS, Benoit S,
Plebani M and Lippi G: Hematologic, biochemical and immune
biomarker abnormalities associated with severe illness and
mortality in coronavirus disease 2019 (COVID-19): A meta-analysis.
Clin Chem Lab Med. 58:1021–1028. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lippi G and Plebani M: Laboratory
abnormalities in patients with COVID-2019 infection. Clin Chem Lab
Med. 58:1131–1134. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Vinutha M, Sharma UR, Swamy G, Rohini S,
Vada S, Janandri S, Haribabu T, Taj N, Gayathri SV, Jyotsna SK and
Mudagal MP: COVID-19-related liver injury: Mechanisms, diagnosis,
management; its impact on pre-existing conditions, cancer and liver
transplant: A comprehensive review. Life Sci.
356(123022)2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Qiu D, Cao W, Zhang Y, Hao H, Wei X, Yao
L, Wang S, Gao Z, Xie Y and Li M: COVID-19 infection, drugs, and
liver injury. J Clin Med. 14(7228)2025.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Genovés P, García D, Cejalvo D, Martin A,
Zaragoza C, Toledo AH, Toledo-Pereyra LH and Lloris-Carsi JM:
Pentoxifylline in liver ischemia and reperfusion. J Invest Surg.
27:114–124. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ward A and Clissold SP: Pentoxifylline. A
review of its pharmacodynamic and pharmacokinetic properties, and
its therapeutic efficacy. Drugs. 34:50–97. 1987.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ji Q, Zhang L, Lv R, Jia H and Xu J:
Pentoxifylline decreases up-regulated nuclear factor kappa B
activation and cytokine production in the rat retina following
transient ischemia. Ophthalmologica. 220:217–224. 2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cerda-Cruz CR, Vazquez-Urrutia JR,
Ortiz-Lazareno PC, Villaseñor-García MM, Cruz-Lozano JR,
Hernández-Flores G and Bravo-Cuellar A: Chemotherapy with a
molecular rational basis, pentoxifylline as a promising antitumor
drug. Ann Med Surg (Lond). 87:1506–1528. 2025.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Pammi M and Haque KN: Pentoxifylline for
treatment of sepsis and necrotising enterocolitis in neonates.
Cochrane Database Syst Rev. 6(CD004205)2023.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Windmeier C and Gressner AM:
Pharmacological aspects of pentoxifylline with emphasis on its
inhibitory actions on hepatic fibrogenesis. Gen Pharmacol.
29:181–196. 1997.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gupta SK, Johnson RM, Mather KJ, Clauss M,
Rehman J, Saha C, Desta Z and Dubé MP: Anti-inflammatory treatment
with pentoxifylline improves HIV-related endothelial dysfunction: A
pilot study. AIDS. 24:1377–1380. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wang Y, Zhang T, Zhao H, Qi C, Ji X, Yan
H, Cui R, Zhang G, Kang Y and Shi G: Pentoxifylline enhances
antioxidative capability and promotes mitochondrial biogenesis in
D-galactose-induced aging mice by increasing Nrf2 and PGC-1α
through the cAMP-CREB pathway. Oxid Med Cell Longev.
2021(6695613)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kurul S, Taal HR, Flint RB, Mazela J,
Reiss IKM, Allegaert K and Simons SHP: Protocol: Pentoxifylline
optimal dose finding trial in preterm neonates with suspected late
onset sepsis (PTX-trial). BMC Pediatr. 21(517)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Jiménez-Luévano MÁ, Lerma-Díaz JM,
Hernández-Flores G, Jiménez-Partida MÁ and Bravo-Cuellar A:
Addition of pentoxifylline to pegylated interferon-alpha-2a and
ribavirin improves sustained virological response to chronic
hepatitis C virus: A randomized clinical trial. Ann Hepatol.
12:248–255. 2013.PubMed/NCBI
|
|
28
|
Wahba-Yahav AV: Schamberg's purpura:
Association with persistent hepatitis B surface antigenemia and
treatment with pentoxifylline. Cutis. 54:205–206. 1994.PubMed/NCBI
|
|
29
|
Sebastian L, Desai A, Madhusudana SN and
Ravi V: Pentoxifylline inhibits replication of Japanese
encephalitis virus: A comparative study with ribavirin. Int J
Antimicrob Agents. 33:168–173. 2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Patel V and McGurk M: Use of
pentoxifylline and tocopherol in radiation-induced fibrosis and
fibroatrophy. Br J Oral Maxillofac Surg. 55:235–241.
2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Jiménez-Luévano MÁ, Jiménez-Partida AE,
Sierra-Díaz E, Orozco-Alonso E, Villaseñor-García M,
Bravo-Hernández A, Gutiérrez-Ortíz JA, Bravo-Cuellar A and
Hernández-Flores G: Prolonged use of pentoxifylline increases the
life expectancy of patients with compensated cirrhosis: A 20-year
retrospective study. Biomed Rep. 21(173)2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Du J, Ma YY, Yu CH and Li YM: Effects of
pentoxifylline on nonalcoholic fatty liver disease: A
meta-analysis. World J Gastroenterol. 20:569–577. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Jiménez-Luévano MA, Ramírez-Flores S,
Sepúlveda-Castro R, Jiménez-Partida AE, Jiménez-Partida MÁ,
Ruiz-Mercado H, Cortés-Aguilar Y, Bravo-Cuellar A and
Hernández-Flores G: Fulminant hepatitis managed with
pentoxifylline. J Clin Exp Pharmacol. 10:1–5. 2020.
|
|
34
|
Angel MJL, Samuel RF, Paulina RV, Angel
MJP, Georgina HF and Alejandro BC: Management of hepatocarcinoma
with celecoxib and pentoxifylline: Report of three cases. J Clin
Exp Pharmacol. 8:1–6. 2018.
|
|
35
|
Ramzi A, Maya S, Balousha N, Amin M and
Shiha MR: Pentoxifylline in COVID-19 and considerations for its
research in long COVID. Inflamm Res. 73:2057–2068. 2024.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ghasemnejad-Berenji M, Pashapour S and
Sadeghpour S: Pentoxifylline: A drug with antiviral and
anti-inflammatory effects to be considered in the treatment of
coronavirus disease 2019. Med Princ Pract. 30:98–100.
2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Child CG and Turcotte JG: Surgery and
portal hypertension. In: Child CG (ed). The liver and portal
hypertension. Philadelphia: Saunders, pp50-64, 1964.
|
|
38
|
Feret W, Nalewajska M, Wojczyński Ł,
Witkiewicz W, Kłos P, Dziedziejko V and Pawlik A: Pentoxifylline as
a potential adjuvant therapy for COVID-19: Impeding the burden of
the cytokine storm. J Clin Med. 10(5305)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Mostafa-Hedeab G, Al-Kuraishy HM,
Al-Gareeb AI, Jeandet P, Saad HM and Batiha GE: A raising dawn of
pentoxifylline in management of inflammatory disorders in Covid-19.
Inflammopharmacology. 30:799–809. 2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
O'Shea RS, Davitkov P, Ko CW, Rajasekhar
A, Su GL, Sultan S, Allen AM and Falck-Ytter Y: AGA clinical
practice guideline on the management of coagulation disorders in
patients with cirrhosis. Gastroenterology. 61:1615–1627.e1.
2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Fernández-Garibay VM, Ramírez-Mejia MM,
Ponciano-Rodriguez G, Wang R, Qi X and Méndez-Sánchez N: The
mechanisms behind thrombocytopenia in patients with portal
hypertension and chronic liver disease. J Clin Transl Hepato.
l13:986–991. 2025.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Saeed A, Farouk MM, Sabri NA, Saleh MA and
Ahmed MA: Effect of pentoxifylline on endothelial dysfunction,
oxidative stress and inflammatory markers in STEMI patients. Future
Sci OA. 10(FSO967)2024.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Sohail A, Ali H, Patel P, Subramanium S,
Dahiya DS, Sohail AH, Gangwani MK and Satapathy SK: Impact of
metabolic dysfunction-associated steatotic liver disease on
COVID-19 hospitalizations: A propensity-matched analysis of the
United States. World J Virol. 13(91149)2024.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Zoncapè M, Carlin M, Bicego M, Simonetti
A, Ceruti V, Mantovani A, Inglese F, Zamboni G, Sartorio A, Minuz
P, et al: Metabolic-associated fatty liver disease and liver
fibrosis scores as COVID-19 outcome predictors: A machine-learning
application. Intern Emerg Med. 18:2063–2073. 2023.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Salceda-Rivera V, Ortiz-Lazareno PC,
Hernández-Flores G, Vazquez-Urrutia JR, Meza-Arroyo J, Pardo-Zepeda
M, Romo-Rubio H, Barba-Barba C, Sánchez-Zubieta F, Barrón-Gallardo
CA, et al: Very early remission and increased apoptosis with the
use of Pentoxifylline in children with acute lymphoblastic
leukemia. Front Oncol. 14(1401262)2024.PubMed/NCBI View Article : Google Scholar
|
